# ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors

> **NCT02551185** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 20 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** ACY-241

## Key facts

- **NCT ID:** NCT02551185
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-22
- **Primary completion:** 2019-09-30
- **Final completion:** 2019-10-04
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02551185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02551185, "ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02551185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*